IGC Pharma (IGC) CEO Ram Mukunda Buys $601K of Stock
On June 30, 2026, Ram Mukunda made a significant purchase of IGC stock.
Reviewed by automated data checks against the source filing. How we make and check alerts
Ram Mukunda, CEO at IGC Pharma, Inc. ($IGC), bought 2,226,475 shares at an average price of $0.27, worth about $601,148.25, on June 30, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $IGC is up 3.7% after 1 week, down 7.4% after 1 month and down 7.4% to date (from the $0.27 close on Jun 30, 2026).
IGC
IGC Pharma, Inc.
Key Points
- IGC CEO Ram Mukunda bought 2,226,475 shares at $0.27 each on June 30, 2026, totaling $601,148.
- Shares of IGC traded at $0.28 on Wednesday, reflecting ongoing investor activity.
- Insider purchases also included Claudia Grimaldi, while analysts maintain a positive outlook.
Get $IGC trade alerts by text
We text you when insiders, Congress or big funds trade $IGC. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated IGC Pharma, Inc. alert may contain errors. Disclosures
IGC's CEO, Ram Mukunda, made a substantial investment in the company by purchasing 2,226,475 shares on June 30, 2026. The shares were acquired at an average price of $0.27 each, amounting to a total value of $601,148. This transaction was not part of a pre-arranged trading plan, highlighting Mukunda's direct commitment to the company.
Other Institutional Activity in IGC
Geode Capital Management increased its holdings by 182,907 shares, ending with 1,043,384 shares valued at $274,440. Vanguard Capital Management opened a new position with 718,436 shares worth about $188,949. BlackRock maintained its position with 703,798 shares valued at $185,099. Renaissance Technologies reduced its stake by 435,666 shares, holding 483,975 shares valued at $127,285. Vanguard Fiduciary Trust Co also opened a new position, acquiring 415,888 shares worth $109,379.
IGC Pharma, Inc. Stock Down 2.5%
Shares of IGC traded near $0.28 on Wednesday. The stock has been experiencing varied activity, reflecting investor interest. Institutional movements and insider transactions continue to shape the company's trading landscape.
Insider Buying and Selling at IGC Pharma, Inc.
In addition to Ram Mukunda's purchase, Claudia Grimaldi, the Principal Financial Officer, bought 2,048,378 shares at the same price on June 30, 2026. Earlier, on April 1, 2026, Grimaldi sold 138,462 shares, while James Moran executed both a buy and a sell transaction of 130,000 shares each.
Analysts Set New Price Targets
On June 8, 2026, Ascendiant Capital maintained its 'buy' rating on IGC with a price target of $5.50. This continued bullish stance reflects confidence in the company's future prospects. Overall, analysts have a consensus 'buy' recommendation, with a mean target price of $5.50 based on multiple opinions.
Bottom Line
Ram Mukunda's recent purchase of IGC shares signals his confidence in the company's potential. Such insider transactions are closely watched by investors as indicators of future performance. While these insights are based on past actions and filings, they offer a glimpse into the strategic decisions of those at the company's helm.
Related Filing Alerts
Source: Ram Mukunda's Form 4 filing on $IGC (Jun 30, 2026). Find the original filing: IGC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts